Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Bio-Path Holdings (OTC:BPTH) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0....
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and an...
First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction an...
Study Progresses to Fourth Higher 90 mg/m2 Dose CohortCompelling Patient Response Highlighted by Stable Disease and Significant...
Clinical Program OverviewBio-Path's clinical development program consists of one Phase 2 clinical trial, two Phase 1 or 1/1...
